MX9207374A - Preparacion farmaceutica que comprende una hormonade crecimiento o un derivado de la hormona de crecimiento e histidina o un derivado de histidina. - Google Patents

Preparacion farmaceutica que comprende una hormonade crecimiento o un derivado de la hormona de crecimiento e histidina o un derivado de histidina.

Info

Publication number
MX9207374A
MX9207374A MX9207374A MX9207374A MX9207374A MX 9207374 A MX9207374 A MX 9207374A MX 9207374 A MX9207374 A MX 9207374A MX 9207374 A MX9207374 A MX 9207374A MX 9207374 A MX9207374 A MX 9207374A
Authority
MX
Mexico
Prior art keywords
histidine
derivative
growth hormone
pharmaceutical preparation
dissolved
Prior art date
Application number
MX9207374A
Other languages
English (en)
Inventor
Hans Holmegaard Soerensen
Lars Skriver
Annie Rassing Hoelgaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK204691A external-priority patent/DK204691D0/da
Priority claimed from DK136492A external-priority patent/DK136492D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX9207374A publication Critical patent/MX9207374A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

Se proporciona una preparación farmacéutica que comprende una hormona del crecimiento e histidina o un derivado de histidina, como aditivo o sustancia amortiguadora que muestra una muy alta estabilidad contra la desamidación, oxidación y ruptura o separación de los enlaces peptídicos.
MX9207374A 1991-12-20 1992-12-17 Preparacion farmaceutica que comprende una hormonade crecimiento o un derivado de la hormona de crecimiento e histidina o un derivado de histidina. MX9207374A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK204691A DK204691D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
DK136492A DK136492D0 (da) 1992-11-10 1992-11-10 A pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MX9207374A true MX9207374A (es) 1993-07-01

Family

ID=26065653

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9207374A MX9207374A (es) 1991-12-20 1992-12-17 Preparacion farmaceutica que comprende una hormonade crecimiento o un derivado de la hormona de crecimiento e histidina o un derivado de histidina.

Country Status (24)

Country Link
EP (2) EP0618807B1 (es)
JP (2) JP2950617B2 (es)
KR (1) KR100266502B1 (es)
AT (2) ATE227583T1 (es)
AU (1) AU667503B2 (es)
BG (1) BG63075B1 (es)
CA (1) CA2125855C (es)
CZ (1) CZ283361B6 (es)
DE (3) DE10399015I1 (es)
DK (1) DK0618807T3 (es)
ES (2) ES2291264T3 (es)
FI (1) FI115116B (es)
HU (1) HUT69402A (es)
IL (1) IL104152A (es)
MX (1) MX9207374A (es)
NL (1) NL300126I1 (es)
NO (1) NO942300L (es)
NZ (1) NZ246556A (es)
PT (1) PT618807E (es)
RO (1) RO111990B1 (es)
RU (1) RU2122426C1 (es)
SK (1) SK279641B6 (es)
UA (1) UA41502C2 (es)
WO (1) WO1993012812A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
DE69420872T2 (de) * 1994-06-17 2000-01-13 Applied Research Systems Hgh enthaltende pharmazeutische zubereitungen
TW426737B (en) * 1994-06-27 2001-03-21 Hayashibara Biochem Lab Saccharide composition with reduced reducibility, and preparation and uses thereof
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
WO1996021460A1 (en) * 1995-01-13 1996-07-18 Novo Nordisk A/S A stabilized pharmaceutical formulation comprising a growth hormone and x-lys
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6936289B2 (en) 1995-06-07 2005-08-30 Danisco A/S Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
CN1278737A (zh) * 1997-11-12 2001-01-03 阿尔萨公司 减少多肽自结合的方法
EP2311436A1 (en) * 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
KR20080011353A (ko) * 2000-02-24 2008-02-01 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
US6719992B2 (en) 2000-06-26 2004-04-13 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
EP1309312A2 (en) 2000-08-07 2003-05-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
PT1314437E (pt) 2000-08-11 2014-08-29 Chugai Pharmaceutical Co Ltd Preparações estabilizadas contendo anticorpo
BR0209154A (pt) 2001-05-18 2004-07-20 Danisco Processo de preparação de uma massa com uma enzima
EP1585771A4 (en) * 2002-12-31 2006-11-29 Altus Pharmaceuticals Inc COMPLEXES OF PROTEIN CRYSTALS AND IONIC POLYMERS
SG176314A1 (en) 2002-12-31 2011-12-29 Altus Pharmaceuticals Inc Human growth hormone crystals and methods for preparing them
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
DK1776455T3 (da) 2004-07-16 2015-06-22 Dupont Nutrition Biosci Aps Lipolytisk enzym, anvendelser deraf i fødevareindustrien
PT1827483E (pt) * 2004-12-15 2014-09-25 Swedish Orphan Biovitrum Ab Publ Formulações terapêuticas do fator de crescimento de queratinócitos
US7816320B2 (en) * 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
RU2008105545A (ru) * 2005-08-30 2009-10-10 Ново Нордиск Хелс Кеа Аг (Ch) Жидкие препараты пэгилированного гормона роста
WO2007033427A1 (en) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
EP2505593A1 (en) 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
CN101495155A (zh) 2006-07-07 2009-07-29 诺沃-诺迪斯克保健股份有限公司 新的蛋白结合物及其制备方法
US8071544B2 (en) * 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
EP2889043B1 (en) * 2008-12-16 2019-04-10 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
JP5924343B2 (ja) * 2010-09-21 2016-05-25 フェリング ベスローテン フェンノートシャップ 組換えヒト成長ホルモン産生の改善された方法
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
DK2854764T3 (en) 2012-06-05 2019-04-08 Neuroderm Ltd COMPOSITIONS CONTAINING APOMORPHINE AND ORGANIC ACIDS, AND APPLICATIONS THEREOF
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
AU2015416589B2 (en) * 2015-12-10 2021-04-01 Menicon Co., Ltd. Peptide composition
AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
BR112020023860A2 (pt) * 2018-05-25 2021-04-13 Dr. Reddy's Laboratories Ltd. Formulação estável de proteína de fusão, e, métodos para obter uma formulação estável e para aumentar a estabilidade de proteína de fusão
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
DK168790D0 (es) * 1990-07-13 1990-07-13 Novo Nordisk As

Also Published As

Publication number Publication date
EP0618807B1 (en) 2002-11-13
ES2185625T3 (es) 2003-05-01
DE69232847T2 (de) 2003-09-11
AU667503B2 (en) 1996-03-28
FI115116B (fi) 2005-03-15
NL300126I1 (nl) 2003-07-01
RU2122426C1 (ru) 1998-11-27
SK279641B6 (sk) 1999-01-11
CZ283361B6 (cs) 1998-03-18
EP0618807A1 (en) 1994-10-12
IL104152A0 (en) 1993-05-13
HU9401832D0 (en) 1994-09-28
DE69233704T2 (de) 2008-05-21
NO942300L (no) 1994-08-19
BG98806A (bg) 1995-02-28
CZ150794A3 (en) 1995-01-18
FI942906A (fi) 1994-06-17
SK75494A3 (en) 1995-03-08
FI942906A0 (fi) 1994-06-17
CA2125855C (en) 2008-05-13
IL104152A (en) 1998-06-15
ES2291264T3 (es) 2008-03-01
JP2950617B2 (ja) 1999-09-20
KR100266502B1 (ko) 2000-09-15
RO111990B1 (ro) 1997-04-30
PT618807E (pt) 2003-03-31
ATE227583T1 (de) 2002-11-15
EP1197222A2 (en) 2002-04-17
DE69233704D1 (de) 2007-09-13
EP1197222B1 (en) 2007-08-01
RU94045932A (ru) 1997-04-20
WO1993012812A1 (en) 1993-07-08
NO942300D0 (no) 1994-06-17
DK0618807T3 (da) 2003-03-03
AU3344693A (en) 1993-07-28
CA2125855A1 (en) 1993-07-08
UA41502C2 (uk) 2001-09-17
JPH07502516A (ja) 1995-03-16
BG63075B1 (bg) 2001-03-30
JPH11315031A (ja) 1999-11-16
HUT69402A (en) 1995-09-28
NZ246556A (en) 1996-03-26
DE10399015I1 (de) 2012-05-03
DE10399015I2 (de) 2008-08-07
EP1197222A3 (en) 2004-02-04
ATE368472T1 (de) 2007-08-15
DE69232847D1 (de) 2002-12-19

Similar Documents

Publication Publication Date Title
MX9207374A (es) Preparacion farmaceutica que comprende una hormonade crecimiento o un derivado de la hormona de crecimiento e histidina o un derivado de histidina.
NO942299D0 (no) Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin
ES2173197T3 (es) Una formula farmaceutica que contiene hormona de crecimiento e isoleucina.
KR970706840A (ko) 성장호르몬 및 발린으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and valine)
ATE213953T1 (de) Ein wachstumshormon und leucin enthaltende pharmazeutische formulierung
MX9800309A (es) Formulacion farmaceutica estabilizada que comprende una hormona del crecimiento y un peptido que comprende al menos un residuo de aminoacido basico y al menos un residuo de aminoacido acido.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: NOVO NORDISK HEALTH CARE AG